Press Releases
Samsung Biologics to attend BIOPLUS•INTERPHEX KOREA 2024
Samsung Biologics will be attending BIOPLUS•INTERPHEX KOREA 2024 between July 10-12 in Seoul.
Under the theme, the ‘World’s Most Tangible Bio-Healthcare Convention,’ the event will invite over 250 companies and 10,000 industry experts to share their insights and discuss partnership opportunities.
Samsung Biologics will highlight its CDMO competitiveness at its booth throughout the convention. The company will share its capacity expansion plans as well as capabilities in diverse modalities, including ADC and mRNA.
Samsung Biologics is gearing up to provide ADC services, following the completion of its dedicated, standalone facility within this year. In terms of capacity, the company will be able to offer over 1.3 million liters upon the completion of BIO Campus II in 2032.
Samsung Biologics will also participate in a speaking session, where Heonchang Lim, Director of Formulation Development, will introduce DEVELOPICK™, the company’s robust developability assessment tool.
Schedule a meeting in advance with the Samsung Biologics team, and learn more about how we can support your development and manufacturing goals: https://partner.samsungbiologics.com/bioplusinterphexkorea2024
Samsung Biologics will be attending BIOPLUS•INTERPHEX KOREA 2024 between July 10-12 in Seoul.
Under the theme, the ‘World’s Most Tangible Bio-Healthcare Convention,’ the event will invite over 250 companies and 10,000 industry experts to share their insights and discuss partnership opportunities.
Samsung Biologics will highlight its CDMO competitiveness at its booth throughout the convention. The company will share its capacity expansion plans as well as capabilities in diverse modalities, including ADC and mRNA.
Samsung Biologics is gearing up to provide ADC services, following the completion of its dedicated, standalone facility within this year. In terms of capacity, the company will be able to offer over 1.3 million liters upon the completion of BIO Campus II in 2032.
Samsung Biologics will also participate in a speaking session, where Heonchang Lim, Director of Formulation Development, will introduce DEVELOPICK™, the company’s robust developability assessment tool.
Schedule a meeting in advance with the Samsung Biologics team, and learn more about how we can support your development and manufacturing goals: https://partner.samsungbiologics.com/bioplusinterphexkorea2024